Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Pitfalls and challenges of the purinergic signaling cascade in obesity

Full text
Author(s):
de Oliveira, Miriane [1] ; Mathias, Lucas Solla [1] ; de Sibio, Maria Teresa [1] ; Noronha-Matos, Jose Bernardo [2, 3] ; Costa, Maria Adelina [2, 3, 4] ; Nogueira, Celia Regina [1] ; Correia-de-Sa, Paulo [2, 3]
Total Authors: 7
Affiliation:
[1] Sao Paulo State Univ UNESP, Botucatu Med Sch, Dist Rubiao Jr S-N, BR-18618000 Botucatu, SP - Brazil
[2] Univ Porto ICBAS UP, Inst Ciencias Biomed Abel Salazar, Lab Farmacol & Neurobiol, Dept Imunofisiol & Farmacol, Porto - Portugal
[3] Univ Porto ICBAS UP, Inst Ciencias Biomed Abel Salazar, Ctr Drug Discovery & Innovat Med MedInUP, Porto - Portugal
[4] Univ Porto ICBAS UP, Inst Ciencias Biomed Abel Salazar, Dept Quim, Porto - Portugal
Total Affiliations: 4
Document type: Journal article
Source: Biochemical Pharmacology; v. 182, DEC 2020.
Web of Science Citations: 0
Abstract

Obesity is a worldwide health problem which have reached pandemic proportions, now also including low and middle-income countries. Excessive or abnormal fat deposition in the abdomen especially in the visceral compartment is tightly associated with a high metabolic risk for arterial hypertension, type II diabetes, cardiovascular diseases, musculoskeletal disorders (especially articular degeneration) and some cancers. Contrariwise, accumulation of fat in the subcutaneous compartment has been associated with a neutral metabolic impact, favoring a lower risk of insulin resistance. Obesity results more often from an avoidable imbalance between food consumption and energy expenditure. There are several recommended strategies for dealing with obesity, including pharmacological therapies, but their success remains incomplete and may not compensate the associated adverse effects. Purinergic signaling operated by ATP and its metabolite, adenosine, has attracted increasing attention in obesity. The extracellular levels of purines often reflect the energy status of a given cell population. Adenine nucleotides and nucleosides fine tuning control adipogenesis and mature adipocytes function via the activation of P2 and P1 purinoceptors, respectively. These features make the purinergic signaling cascade a putative target for therapeutic intervention in obesity and related metabolic syndromes. There are, however, gaps in our knowledge regarding the role of purines in adipocyte precursors differentiation and mature adipocytes functions, as well as their impact among distinct adipose tissue deposits (e.g. white vs. brown, visceral vs. subcutaneous), which warrants further investigations before translation to clinical trials can be made. (AU)

FAPESP's process: 16/03242-3 - Global transcriptome analysis of primary subcutaneous preadipocytes~ normal, human: identification of genes regulated by triiodothyronine and irisin
Grantee:Miriane de Oliveira
Support Opportunities: Scholarships in Brazil - Post-Doctorate